PAN Foundation Launches COVID-19 Treatment and Prevention Fund to Help At-Risk Medicare Beneficiaries Pay for Treatment, Groceries and Other Critical Services

PAN Foundation, is an independent charitable organization dedicated to helping underinsured patients access critical medical care. Today they announced that it will offer financial assistance to Americans with existing medical conditions who have COVID-19 or are quarantined because of the virus.

Through this comprehensive fund, PAN will provide a $300 grant to qualifying Medicare beneficiaries with cancer, chronic or rare diseases who have also been diagnosed with COVID-19 or directed to self-quarantine by their healthcare provider or a government agency. Grant recipients can use the funds for treatment co-pays, prescription and over-the-counter medications, medical supplies and other important expenses related to COVID-19 prevention and treatment, including transportation to medical appointments and groceries, meals and food delivery services.

“The COVID-19 pandemic is a stark reminder of the importance of our mission to ensure that every American can afford the healthcare they need. While we don’t know the full impact of this outbreak, we’re dedicated to doing everything we can to protect and support the most vulnerable members of our society,” said PAN President and CEO Daniel J. Klein. “As Medicare beneficiaries and people with serious health conditions learn to cope with this rapidly evolving situation, we’re committed to providing assistance to help those who need it most so they can focus on getting better and worry less about the cost of care.”

The results of a recent poll by the Commonwealth Foundation highlight the collective worry of Americans about their ability to afford medical treatment: 68 percent of adults said that the out-of-pocket costs they might have to pay would be very or somewhat important in their decision to get treatment if they had symptoms of the coronavirus.

The COVID-19 Treatment and Prevention Fund is currently open for applicants who have annual household incomes up to 400 percent of the federal poverty level. Eligible patients can learn more about the fund on our website or by calling PAN at 1-866-316-7263 from Monday through Friday, 9 a.m. to 7 p.m. ET.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version